EUCTR2005-001596-34-DE进行中（未招募）不适用
Multicentre phase II trial of Bendamustine in combination with rituximab for patients with previously untreated or relapsed chronic lymphocytic leukemia - CLL2M
niversität zu Köln0 个研究点目标入组 95 人开始时间: 2005年12月7日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 95
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.18 years of age or older
- •2.Diagnosis of B-CLL in need of treatment
- •- Previously untreated Binet C or Binet B with need of treatment according to
- •NCIcriteria
- •- Relapsed or refractory disease after at least one but not more than 3 prior regimens. Patients who previously received bendamustine must have had at least a partial response with duration of response of at least six months. These patients must have completed treatment for more than six months.
- •3.World Health Organization performance status of 0-2
- •4.Life expectancy >12 weeks
- •5.Anti-cancer therapy, major surgery, or irradiation was completed >3 weeks before registration in this study. Patient must have recovered from the acute side effects incurred as a result of previous therapy.
- •6.Serum creatinine =1.5 the institutional upper limit of normal (ULN) or Creatinine clearance >30 ml/min/1.73 m²
- •7.Adequate liver function as indicated by a total bilirubin, AST, and ALT =2 the institutional ULN value, unless directly attributable to the patient’s tumor.
- •8.Female patients with childbearing potential must have a negative serum pregnancy test within two weeks of first dose of study drug(s). Male and female patients must agree to use an effective contraceptive method while on study treatment and for a minimum of six months following study therapy.
- •9.Signed, written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Previously treated with >3 prior regimens for B-CLL.
- •2.Known central nervous system (CNS) involvement with B-CLL.
- •3.Patients who have progressed with more aggressive B-cell cancers such as Richter’s syndrome.
- •4.History of anaphylaxis following exposure to monoclonal antibodies.
- •5.Known to be human immunodeficiency virus (HIV), hepatitis B, or C positive.
- •6.Active infection or history of severe infection (grade 4) within 3 months prior to study registration.
- •7.Medical condition requiring prolonged use of oral corticosteroids .. (> 1 month).
- •8.Use of investigational agents within 30 days prior to study randomization.
- •9.Active secondary malignancy.10.ANC <1.5x109/L or platelet count <75x109/L, unless due to bone marrow involvement of CLL.
- •11.Other severe, concurrent diseases, including tuberculosis, mental disorders, serious cardiac functional capacity (Class III or IV as defined by the New York Heart Association Classification), severe diabetes, severe hypertension, pulmonary disease (chronic obstructive pulmonary disease [COPD] with hypoxemia), or major organ malfunction (liver, kidney) that could interfere with the patient’s ability to participate in the study.
- •12.Pregnant or nursing women.
- •13.Any circumstance at the time of study entry that would preclude completion of the study or the required follow-up.
- •14.Participation in another clinical trial
研究者
相似试验
招募中
2 期
Clinical trials for HDC / ASCT indication rrDLBCRelapsed or recurrent diffuse large B-cell lymphomaJPRN-jRCTs071210121Terui Yasuhito20
进行中（未招募）
不适用
A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular Non-Hodgkin’s LymphomaPatients with advanced untreated Indolent non Follicular non-Hodgkin LymphomasMedDRA version: 14.1Level: PTClassification code 10065856Term: Non-Hodgkin's lymphoma unspecified histology indolentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019248-37-ITFONDAZIONE ITALIANA LINFOMI ONLUS
进行中（未招募）
不适用
Multicenter Phase II Study of Bendamustine, Velcade (Bortezomib) and Dexamethasone (BVD) in the treatment of elderly patients (> or =65 years) with multiple myeloma in 1st relapse or refractory to 1st line therapy - BVDPatient with Multiple Myeloma (MM) in 1st relapse or refractory to 1st line therapy, having received 1st line therapy with conventional chemotherapy without stem cell transplantation (patients 65 years or older or younger than 65 years and ineligible for high-dose therapy plus stem cell transplantation).MedDRA version: 9.1Level: LLTClassification code 10028228Term: Multiple myelomaEUCTR2009-012359-91-FRIntergroupe Francophone du Myélome70
招募中
1 期
Phase 1/2 study of the combination of Bendamustine and Rituximab for treatment of relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphomaJPRN-UMIN000005428Department of Hematology, International Medical Center, Saitama Medical University40
招募中
1 期
Phase 1/2 study of the combination of Bendamustine and Rituximab for treatment of elderly relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.JPRN-UMIN000006513Kinki University School of Medecine Division of Hematology43